PK of LY2409021 in Subjects with Varying Degrees of Renal Function

• Research type

  Research Study

• Full title

  Pharmacokinetics of LY2409021 Following Administration to Subjects with Varying Degrees of Renal Function

• IRAS ID

  122304

• Contact name

  Amitava Ganguli

• Sponsor organisation

  Eli Lilly and Company

• Eudract number

  2012-004978-26

• Research summary

  Eli Lilly and Company are currently developing LY2409021 as a treatment for high blood sugar in patients with type 2 diabetes mellitus. LY2409021 is a potent and selective antagonist (blocks action of a receptor) of the human glucagon receptor. Blood sugar levels are normally regulated by a balance between the opposing actions of glucagon, which increases glucose release from the liver, and insulin, which suppresses glucose release and stimulates glucose storage. It is thought that antagonism of the glucagon receptor by LY2409021 in type 2 diabetes will help to prevent glucose overproduction and will improve blood sugar levels. Renal (kidney) failure is a very common complication of diabetes mellitus. The purpose of this study is to evaluate the effects of varying degrees of renal failure on the levels of LY2409021 in the bloodstream and to compare with the levels seen in subjects with normal renal function.

• REC name

  North West - Greater Manchester Central Research Ethics Committee

• REC reference

  13/NW/0050

• Date of REC Opinion

  11 Mar 2013

• REC opinion

  Further Information Favourable Opinion